North America Anticoccidial Drugs Market Size (2024 - 2029)

The North America Anticoccidial Drugs Market is projected to experience growth driven by factors such as the increasing incidence of coccidiosis in both food-producing and companion animals, along with heightened awareness of animal health in the region. Advancements in veterinary healthcare are significantly contributing to the market's expansion. However, the market's growth may be challenged by the adoption of alternative treatments like vaccines and herbal remedies for coccidiosis.

Home Market Analysis Healthcare Research Animal Health Research Animal Medicine Research Animal Drugs Research Anti Infectives Animal Drugs Research North America Anticoccidial Drugs Industry Market Size

Market Size of North America Anticoccidial Drugs Industry

anticoccidial drugs market
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 537.19 Million
Market Size (2029) USD 673.61 Million
CAGR (2024 - 2029) 4.63 %

Major Players

North America Anticoccidial Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

North America Anticoccidial Drugs Market Analysis

The North America Anticoccidial Drugs Market size is estimated at USD 537.19 million in 2024, and is expected to reach USD 673.61 million by 2029, growing at a CAGR of 4.63% during the forecast period (2024-2029).

Anticoccidial drugs market is being driven by factors such as the rising incidence of coccidiosis in food-producing animals and companion animals, coupled with the rising awareness regarding animal health across the North America.

Also, advancements in veterinary healthcare are one of the major factors fueling the growth of the market studied across the world. For instance, in April 2019, Creative Diagnostics announced the launch of a series of innovative anticoccidial drug analysis products and services for its global clients.

Moreover, In August 2020, Merck Animal Health announced the acquisition of completion of its previously announced acquisition of the worldwide rights to VECOXAN which used for prevention of coccidiosis in calves and lambs, from Elanco Animal Health.

However, the use of alternative treatments, such as vaccines and herbal remedies, to treat Coccidiosis is likely to hamper the growth of anticoccidial drugs market across the world.

North America Anticoccidial Drugs Industry Segmentation

Coccidiosis is one of the most frequent and prevalent parasitic diseases among domesticated animals and its symptoms include weight loss, mild intermittent to severe diarrhoea, faeces containing mucus or blood, dehydration, and decreased breeding. Coccidiosis is caused by single-celled parasites (protozoa) called Eimeria, which undergo a simple life cycle in the gut. Any drug used to combat the progression of coccidiosis in birds or animals, both food-producing and non-food producing, is termed as an anticoccidial.

Need A Different Region Or Segment?
Customize Now

North America Anticoccidial Drugs Market Size Summary

The North America Anticoccidial Drugs Market is poised for significant growth, driven by the increasing prevalence of coccidiosis in both food-producing and companion animals, alongside heightened awareness of animal health. The market is benefiting from advancements in veterinary healthcare, with companies like Creative Diagnostics and Merck Animal Health making notable strides in drug development and acquisitions. Despite the potential challenges posed by alternative treatments such as vaccines and herbal remedies, the market continues to expand, supported by the historical success of polyether ionophore anticoccidials like monensin. These drugs are favored for their broad-spectrum activity and lack of significant resistance, making them a staple in animal feed formulations.

The market landscape is characterized by fragmentation and competitiveness, with several key players holding substantial market shares. Companies such as Zoetis Animal Healthcare, Phibro Animal Health Corporation, and Huvepharma are among the leading entities driving market dynamics. The ionophore anticoccidial segment, in particular, is expected to witness robust growth due to its widespread use and regulatory support, as evidenced by the US Food and Drug Administration's reports on antimicrobial sales. This competitive environment, coupled with strategic developments and regulatory endorsements, positions the North America Anticoccidial Drugs Market for continued expansion in the coming years.

Explore More

North America Anticoccidial Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increased Incidence of Coccidiosis

      2. 1.2.2 Advancements in Veterinary Healthcare

    3. 1.3 Market Restraints

      1. 1.3.1 Availability of Alternative Treatment Options in the Market

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Drug Type

      1. 2.1.1 Ionophore Anticoccidials

      2. 2.1.2 Chemical Derivative Anticoccidials

    2. 2.2 By Animal

      1. 2.2.1 Poultry

      2. 2.2.2 Swine

      3. 2.2.3 Fish

      4. 2.2.4 Cattle

      5. 2.2.5 Companion Animals

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

North America Anticoccidial Drugs Market Size FAQs

The North America Anticoccidial Drugs Market size is expected to reach USD 537.19 million in 2024 and grow at a CAGR of 4.63% to reach USD 673.61 million by 2029.

In 2024, the North America Anticoccidial Drugs Market size is expected to reach USD 537.19 million.

North America Anticoccidial Drugs Market Report Snapshots

North America Anticoccidial Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)